<DOC>
	<DOCNO>NCT00086034</DOCNO>
	<brief_summary>The primary purpose study find motexafin gadolinium may effective treatment patient non-Hodgkin 's lymphoma ( NHL ) . Secondly , safety side effect motexafin gadolinium evaluate .</brief_summary>
	<brief_title>Study Motexafin Gadolinium Treatment Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>≥ 18 year old Refractory relapse indolent NHL . Eligible WHO histologies include follicular NHL ( Grades 1 , 2 , 3 ) ; marginal zone nodal ; marginal zone splenic ; mucosaassociated lymphoid tissue ( MALT ) type Failed ≥ 1 previous regimen , one must contain rituximab either single agent combination chemotherapy ECOG performance status score either 0 1 Willing able provide write informed consent Laboratory value : Platelet count &lt; 50,000/µL AST ALT &gt; 2 x upper limit normal ( ULN ) Total bilirubin &gt; 2 x ULN Creatinine &gt; 2.0 mg/dL Greater three prior regimen ( regimen define treatment NHL give disease progression ) Uncontrolled hypertension Known history porphyria , G6PD deficiency , HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Indolent lymphoma</keyword>
	<keyword>Relapsed lymphoma</keyword>
	<keyword>Refractory lymphoma</keyword>
	<keyword>Motexafin gadolinium</keyword>
</DOC>